A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JJCO/HYH064PMID 15333686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.

  2003cited by this paper
• Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study

  2003cited by this paper
• Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

  2003cited by this paper
• Prostate cancer — an overview

  2003cited by this paper
• Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

  2002cited by this paper
• A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.

  2002cited by this paper
• Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma

  2002cited by this paper
• Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

  2002cited by this paper
• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  2001cited by this paper
• A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

  2000cited by this paper
• Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.

  1999cited by this paper
• Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV).

  1999cited by this paper
• Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

  1999cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

  1997cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

  1994cited by this paper
• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993cited by this paper
• Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

  1993cited by this paper
• Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group.

  1990cited by this paper
• Quality of life and treatment of hormone resistant metastatic prostatic cancer

  1990cited by this paper
• Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.

  1990cited by this paper
• Flutamide in hormone-resistant prostatic cancer.

  1990cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• The endocrinology and developmental biology of the prostate.

  1987cited by this paper
• A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

  1985cited by this paper
• A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.

  1985cited by this paper
• Ketoconazole therapy for advanced prostate cancer.

  1984cited by this paper
• Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.

  1983cited by this paper

• A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

  2007cites this paper
• Head and Neck

  2005cites this paper